Bank yearly blood from cancer survivors so future tests can be validated
To prove a leftover-cancer test works you need blood taken years before relapse. Collecting and freezing yearly samples now makes every future test testable.
Every new MRD or early detection assay needs pre-diagnostic or pre-relapse serial specimens, which take years to accumulate and cannot be created retrospectively. A prospective survivor cohort of 50,000 people banking annual plasma, with registry-linked outcomes and open access rules, would become the shared validation substrate for the whole field.
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Data silos · Records, scans, genomes and outcomes sit in separate systems that cannot talk. Every patient's experience is lost to the next.
- Most lethal cancers are found late · Screening exists for only a few cancers. Pancreatic, ovarian, liver, oesophageal and most lung cancers are found when cure is unlikely.
Pages like this
not linked directly; found by shared links- IdeaTake the blood test, and give the drug, at the right time of day
Shares Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- PersonAsh A. Alizadeh
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaHPV circulating tumour DNA to guide cervical cancer therapy
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaRead the spinal fluid to track brain tumours without opening the skull
Shares Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- TechnologyctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)
Shares Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaMandatory interval-cancer audit for every blood-based screening test
Shares SEER (Surveillance, Epidemiology, and End Results), Multi-cancer early detection (MCED), Most lethal cancers are found late, Liquid biopsy (ctDNA).
- IdeaPush residual disease detection a hundredfold deeper with whole-genome methods
Shares Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Most lethal cancers are found late.
- IdeaBreak the neutrophil DNA nets that catch tumour cells after surgery
Shares Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).